Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05187377 · ClinicalTrials.gov registry record · Phase 2
A Controlled Trial of Growth Hormone in Phelan-McDermid Syndrome and Idiopathic Autism
A Phase 2 study, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT05187377 is a Phase 2 study that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 32 participants.
The verdict
NCT05187377, a Phase 2 study, has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
This clinical trial will use growth hormone as a novel treatment for Phelan-McDermid syndrome (PMS) and idiopathic autism. A double-blind, placebo-controlled crossover trial design will be used in 30 children with idiopathic autism and 15 children with PMS to evaluate the the effects of growth hormone on visual evoked potentials (VEPs), socialization, language, and repetitive behaviors. The researchers expect to provide evidence for the feasibility of using VEPs in PMS, and to show support for growth hormone in ameliorating clinical symptoms of ASD.
Interventions
- DRUG Saline
- DRUG Growth Hormone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2022-01-19 |
| Est. Completion | 2025-02-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05187377
The ClinicalTrials.gov registry entry for NCT05187377 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Saline is the first listed.
NCT05187377 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05187377 about?
NCT05187377 is a clinical study titled "A Controlled Trial of Growth Hormone in Phelan-McDermid Syndrome and Idiopathic Autism". This clinical trial will use growth hormone as a novel treatment for Phelan-McDermid syndrome (PMS) and idiopathic autism. A double-blind, placebo-controlled crossover trial design will be used in 30 children with idiopathic autism and 15 children with PMS to evaluate the the effects of growth hormo...
What is the current status of trial NCT05187377?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2022-01-19. Estimated completion is 2025-02-05.
What interventions are being tested in trial NCT05187377?
The interventions under investigation include: Saline (DRUG), Growth Hormone (DRUG).
Who is sponsoring clinical trial NCT05187377?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.